Evidence map›Paper›PMID 42873648›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Targeted Perturbation of Mitochondrial Energy Metabolism via Thermoelectric Nanoflowers for Enhanced Cuproptosis Echoed With Immunotherapy.

Haoyang Du, Chao Xu, Hao Wang, Bo Peng, Peng Liu, Wei Gao, Tao Ye, Xinyuan Yu, Ying Shi, Jiaxin Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Haoyang Du *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Chao Xu *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Hao WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Bo PengState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Peng LiuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Wei GaoState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Tao YeState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Xinyuan YuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Ying ShiState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.ORCID https://orcid.org/0009-0007-6534-2991
Jiaxin LiuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Tiancong ZhaoLaboratory of Advanced Materials, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0003-1995-2274
Bin SunState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.ORCID https://orcid.org/0000-0003-2583-4493
Piaoping YangKey Laboratory of Superlight Materials and Surface Technology, College of Materials Science and Chemical Engineering, Ministry of Education, Harbin Engineering University, Harbin, People's Republic of China.ORCID https://orcid.org/0000-0002-9555-1803
Manjie ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmaceutics, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.ORCID https://orcid.org/0009-0006-5527-756X

Funding

China Postdoctoral Science Foundation 2023M730827Heilongjiang Postdoctoral Science Foundation LBH-223123National Natural Science Foundation of China 22002096National Natural Science Foundation of China 32501103
6 · The paper itself

Abstract

Cuproptosis, a novel anti-cancer mechanism, holds significant potential for triggering sequential immunotherapy to enhance anti-cancer efficacy. However, this cascade effect is often limited by copper efflux mechanisms mediated by the copper-transporting ATPase (ATP7B), which reduces intracellular copper accumulation and negates cuproptosis. Here, we designed a mitochondria-targeting thermoelectric nanoplatform to interfere with the electron transport chain (ETC) of mitochondria, causing adenosine triphosphate (ATP) outage to inhibit ATP7B function, thereby enhancing cuproptosis to achieve a synergistic immunotherapy effect. The nanoplatform was fabricated on a thermoelectric copper telluride (Cu

Indexed as

copper transporter ATPasecuproptosiselectron transport chainimmunotherapythermoelectric materials

Identifiers

PMID42873648
PMCPMC13667398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.